ADCT
ADC Therapeutics SA
NYSE · Healthcare · Biotechnology · CH
$1.44
+3.23%Year over year
Reported trailing growth
- Revenue
- +2.0%
- EBITDA
- +24.1%
- EBIT
- +29.5%
- EPS
- +57.8%
- Free cash flow
- +20.0%
- Operating cash flow
- +19.7%
Forward estimates
Based on analyst estimates
- Revenue
- +14.6%
- EBITDA
- +36.7%
- EPS
- -5.6%
Three-year CAGR
- Revenue
- -27.1%
- EBITDA
- +13.0%
- EBIT
- +17.0%
- Net income
- +9.6%
- EPS
- +30.9%
- Free cash flow
- -13.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026